Nuvalent - Public Comps and Valuation Multiples

Nuvalent Overview

About Nuvalent

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company’s operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Founded

2017

HQ

Employees

142

Website

nuvalent.com

Sectors

Drug Development & Therapeutics
BioTech

Financials

LTM Revenue n/a

LTM EBITDA -$294M

EV

$3.9B

Valuation Multiples

Multiples.vc

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Nuvalent Financials

Nuvalent has a last 12-month revenue of n/a and a last 12-month EBITDA of -$294M.

In the most recent fiscal year, Nuvalent achieved revenue of n/a and an EBITDA of -$280M.

Nuvalent expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Nuvalent valuation multiples based on analyst estimates

Nuvalent P&L

	FY 2023	FY 2024	FY 2025	LTM	NTM
Revenue	n/a	n/a	XXX	XXX	XXX
Gross Profit	n/a	n/a	XXX	XXX	XXX
Gross Margin	NaN%	NaN%	XXX	XXX	XXX
EBITDA	-$149M	-$280M	XXX	XXX	XXX
EBITDA Margin	-Infinity%	-Infinity%	XXX	XXX	XXX
Net Profit	-$81.9M	-$126M	XXX	XXX	XXX
Net Margin	-Infinity%	-Infinity%	XXX	XXX	XXX
Net Debt	n/a	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

Nuvalent Stock Performance

As of April 15, 2025, Nuvalent's stock price is $70.

Nuvalent has current market cap of $5.0B, and EV of $3.9B.

See Nuvalent trading valuation data

Nuvalent Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$3.9B	$5.0B	XXX	XXX	XXX	XXX	$-4.14

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Nuvalent Valuation Multiples

As of April 15, 2025, Nuvalent has market cap of $5.0B and EV of $3.9B.

Nuvalent's trades at n/a LTM EV/Revenue multiple, and -13.3x LTM EBITDA.

Analysts estimate Nuvalent's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See valuation multiples for Nuvalent and 10K+ public comps

Nuvalent Financial Valuation Multiples

	FY 2024	FY 2025E	FY 2026E	FY 2027E
EV	$3.9B	XXX	XXX	XXX
EV/Revenue	n/a	XXX	XXX	XXX
EV/EBITDA	-13.9x	XXX	XXX	XXX
P/E	-19.2x	XXX	XXX	XXX
P/E/Growth	n/a	XXX	XXX	XXX
EV/FCF	-21.0x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Nuvalent Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Nuvalent Valuation Multiples

Nuvalent's NTM/LTM revenue growth is Infinity%

Nuvalent's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $2.0M for the same period.

Over next 12 months, Nuvalent's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .

Analysts estimate Nuvalent's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See operational valuation multiples for Nuvalent and other 10K+ public comps

Nuvalent Operational Valuation Multiples

	FY 2024	NTM	FY 2025E	FY 2026E	FY 2027E
Revenue Growth	n/a	XXX	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	XXX	XXX	XXX
EBITDA Growth	88%	XXX	XXX	XXX	XXX
Rule of 40 (SaaS-only)	n/a	XXX	XXX	XXX	XXX
Revenue per Employee	n/a	XXX	XXX	XXX	XXX
Opex per Employee	$2.0M	XXX	XXX	XXX	XXX
S&M Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
G&A Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
R&D Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
Opex to Revenue	n/a	XXX	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry